<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39310374</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-889X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in molecular biosciences</Title><ISOAbbreviation>Front Mol Biosci</ISOAbbreviation></Journal><ArticleTitle>A potential allosteric inhibitor of SARS-CoV-2 main protease (M<sup>pro</sup>) identified through metastable state analysis.</ArticleTitle><Pagination><StartPage>1451280</StartPage><MedlinePgn>1451280</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1451280</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmolb.2024.1451280</ELocationID><Abstract><AbstractText>Anti-COVID19 drugs, such as nirmatrelvir, have been developed targeting the SARS-CoV-2 main protease, M<sup>pro</sup>, based on the critical requirement of its proteolytic processing of the viral polyproteins into functional proteins essential for viral replication. However, the emergence of SARS-CoV-2 variants with M<sup>pro</sup> mutations has raised the possibility of developing resistance against these drugs, likely due to therapeutic targeting of the M<sup>pro</sup> catalytic site. An alternative to these drugs is the development of drugs that target an allosteric site distant from the catalytic site in the protein that may reduce the chance of the emergence of resistant mutants. Here, we combine computational analysis with <i>in vitro</i> assay and report the discovery of a potential allosteric site and an allosteric inhibitor of SARS-CoV-2 M<sup>pro</sup>. Specifically, we identified an M<sup>pro</sup> metastable state with a deformed catalytic site harboring potential allosteric sites, raising the possibility that stabilization of this metastable state through ligand binding can lead to the inhibition of M<sup>pro</sup> activity. We then performed a computational screening of a library (∼4.2 million) of drug-like compounds from the ZINC database and identified several candidate molecules with high predicted binding affinity. MD simulations showed stable binding of the three top-ranking compounds to the putative allosteric sites in the protein. Finally, we tested the three compounds <i>in vitro</i> using a BRET-based M<sup>pro</sup> biosensor and found that one of the compounds (ZINC4497834) inhibited the M<sup>pro</sup> activity. We envisage that the identification of a potential allosteric inhibitor of M<sup>pro</sup> will aid in developing improved anti-COVID-19 therapy.</AbstractText><CopyrightInformation>Copyright © 2024 Fatima, Geethakumari, Ahmed and Biswas.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fatima</LastName><ForeName>Asma</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Biological and Biomedical Sciences, College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geethakumari</LastName><ForeName>Anupriya M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Division of Biological and Biomedical Sciences, College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Wesam S</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Division of Biological and Biomedical Sciences, College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biswas</LastName><ForeName>Kabir H</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Division of Biological and Biomedical Sciences, College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Mol Biosci</MedlineTA><NlmUniqueID>101653173</NlmUniqueID><ISSNLinking>2296-889X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">MD simulation</Keyword><Keyword MajorTopicYN="N">Mpro</Keyword><Keyword MajorTopicYN="N">ZINC15</Keyword><Keyword MajorTopicYN="N">allosteric regulator</Keyword><Keyword MajorTopicYN="N">metastable states</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39310374</ArticleId><ArticleId IdType="pmc">PMC11413593</ArticleId><ArticleId IdType="doi">10.3389/fmolb.2024.1451280</ArticleId><ArticleId IdType="pii">1451280</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmed W. S., Biswas K. H., Philip A. M. (2022). Decreased interfacial dynamics caused by the N501Y mutation in the SARS-CoV-2 S1 spike: ACE2 complex. Front. Mol. Biosci. 506. 10.3389/fmolb.2022.846996</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2022.846996</ArticleId><ArticleId IdType="pmc">PMC9355283</ArticleId><ArticleId IdType="pubmed">35936792</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed W. S., Geethakumari A. M., Sultana A., Fatima A., Philip A. M., Uddin S. M. N., et al. (2024). A slow but steady nanoLuc: R162A mutation results in a decreased, but stable, nanoLuc activity. Int. J. Biol. Macromol. 269, 131864. 10.1016/j.ijbiomac.2024.131864</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2024.131864</ArticleId><ArticleId IdType="pubmed">38692549</ArticleId></ArticleIdList></Reference><Reference><Citation>Altamash T., Ahmed W., Rasool S., Biswas K. H. (2021). Intracellular ionic strength sensing using NanoLuc. Int. J. Mol. Sci. 22, 677. 10.3390/ijms22020677</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22020677</ArticleId><ArticleId IdType="pmc">PMC7826950</ArticleId><ArticleId IdType="pubmed">33445497</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzyoud L., Ghattas M. A., Atatreh N. (2022). Allosteric binding sites of the SARS-CoV-2 main protease: potential targets for broad-spectrum anti-coronavirus agents. Drug Des. Devel Ther. 16, 2463–2478. 10.2147/dddt.S370574</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/dddt.S370574</ArticleId><ArticleId IdType="pmc">PMC9356625</ArticleId><ArticleId IdType="pubmed">35941927</ArticleId></ArticleIdList></Reference><Reference><Citation>Arafet K., Serrano-Aparicio N., Lodola A., Mulholland A. J., González F. V., Świderek K., et al. (2020). Mechanism of inhibition of SARS-CoV-2 M(pro) by N3 peptidyl Michael acceptor explained by QM/MM simulations and design of new derivatives with tunable chemical reactivity. Chem. Sci. 12, 1433–1444. 10.1039/d0sc06195f</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/d0sc06195f</ArticleId><ArticleId IdType="pmc">PMC8179034</ArticleId><ArticleId IdType="pubmed">34163906</ArticleId></ArticleIdList></Reference><Reference><Citation>Arshad N., Laurent-Rolle M., Ahmed W. S., Hsu J. C. C., Mitchell S. M., Pawlak J., et al. (2023). SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to down-regulate MHC-I surface expression. Proc. Natl. Acad. Sci. U. S. A. 120, e2208525120. 10.1073/pnas.2208525120</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2208525120</ArticleId><ArticleId IdType="pmc">PMC9910621</ArticleId><ArticleId IdType="pubmed">36574644</ArticleId></ArticleIdList></Reference><Reference><Citation>Astore M. A., Pradhan A. S., Thiede E. H., Hanson S. M. (2024). Protein dynamics underlying allosteric regulation. Curr. Opin. Struct. Biol. 84, 102768. 10.1016/j.sbi.2023.102768</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2023.102768</ArticleId><ArticleId IdType="pubmed">38215528</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat Z. A., Chitara D., Iqbal J., Sanjeev B., Madhumalar A. (2022a). Targeting allosteric pockets of SARS-CoV-2 main protease Mpro. J. Biomol. Struct. Dyn. 40, 6603–6618. 10.1080/07391102.2021.1891141</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2021.1891141</ArticleId><ArticleId IdType="pubmed">33645457</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat Z. A., Chitara D., Iqbal J., Sanjeev B. S., Madhumalar A. (2022b). Targeting allosteric pockets of SARS-CoV-2 main protease M(pro). J. Biomol. Struct. Dyn. 40, 6603–6618. 10.1080/07391102.2021.1891141</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2021.1891141</ArticleId><ArticleId IdType="pubmed">33645457</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat Z. A., Khan M. M., Rehman A., Iqbal J., Sanjeev B. S., Madhumalar A. (2024). MD simulations indicate Omicron P132H of SARS-CoV-2 M(pro) is a potential allosteric mutant involved in modulating the dynamics of catalytic site entry loop. Int. J. Biol. Macromol. 262, 130077. 10.1016/j.ijbiomac.2024.130077</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2024.130077</ArticleId><ArticleId IdType="pubmed">38346625</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian L., Gao F., Zhang J., He Q., Mao Q., Xu M., et al. (2021). Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. Expert Rev. vaccines. 20, 365–373. 10.1080/14760584.2021.1903879</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2021.1903879</ArticleId><ArticleId IdType="pmc">PMC8054487</ArticleId><ArticleId IdType="pubmed">33851875</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas K., Sopory S., Visweswariah S. (2008a). The GAF domain of the cGMP-binding, cGMP-specific phosphodiesterase (PDE5) is a sensor and a sink for cGMP. Biochemistry 47, 3534–3543. 10.1021/bi702025w</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi702025w</ArticleId><ArticleId IdType="pubmed">18293931</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas K. H., Badireddy S., Rajendran A., Anand G. S., Visweswariah S. S. (2015). Cyclic nucleotide binding and structural changes in the isolated GAF domain of Anabaena adenylyl cyclase, CyaB2. PeerJ 3, e882. 10.7717/peerj.882</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.882</ArticleId><ArticleId IdType="pmc">PMC4411481</ArticleId><ArticleId IdType="pubmed">25922789</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas K. H. (2017). Allosteric regulation of proteins: A historical perspective on the development of concepts and techniques. Resonance. 22(1). 37–50. 10.1007/s12045-017-0431-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12045-017-0431-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas K. H., Sopory S., Visweswariah S. S. (2008b). The GAF domain of the cGMP-binding, cGMP-specific phosphodiesterase (PDE5) is a sensor and a sink for cGMP. Biochemistry. 47, 3534–3543. 10.1021/bi702025w</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi702025w</ArticleId><ArticleId IdType="pubmed">18293931</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas K. H., Visweswariah S. S. (2011). Distinct allostery induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ions. J. Biol. Chem. 286, 8545–8554. 10.1074/jbc.M110.193185</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.193185</ArticleId><ArticleId IdType="pmc">PMC3048737</ArticleId><ArticleId IdType="pubmed">21193396</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown D. K., Penkler D. L., Sheik Amamuddy O., Ross C., Atilgan A. R., Atilgan C., et al. (2017). MD-TASK: a software suite for analyzing molecular dynamics trajectories. Bioinformatics 33, 2768–2771. 10.1093/bioinformatics/btx349</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btx349</ArticleId><ArticleId IdType="pmc">PMC5860072</ArticleId><ArticleId IdType="pubmed">28575169</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway E. (2022). Fast-evolving COVID variants complicate vaccine updates. Nature 607, 18–19. 10.1038/d41586-022-01771-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-01771-3</ArticleId><ArticleId IdType="pubmed">35760853</ArticleId></ArticleIdList></Reference><Reference><Citation>Carli M., Sormani G., Rodriguez A., Laio A. (2021). Candidate binding sites for allosteric inhibition of the SARS-CoV-2 main protease from the analysis of large-scale molecular dynamics simulations. J. Phys. Chem. Lett. 12, 65–72. 10.1021/acs.jpclett.0c03182</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jpclett.0c03182</ArticleId><ArticleId IdType="pmc">PMC7755075</ArticleId><ArticleId IdType="pubmed">33306377</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik M., Kuppalli K., Kindrachuk J., Peiris M. (2020). Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ 371, m3862. 10.1136/bmj.m3862</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3862</ArticleId><ArticleId IdType="pubmed">33097561</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan H. T. H., Moesser M. A., Walters R. K., Malla T. R., Twidale R. M., John T., et al. (2021). Discovery of SARS-CoV-2 Mpro peptide inhibitors from modelling substrate and ligand binding. Chem. Sci. 12, 13686–13703. 10.1039/D1SC03628A</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D1SC03628A</ArticleId><ArticleId IdType="pmc">PMC8549791</ArticleId><ArticleId IdType="pubmed">34760153</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L. L., Lu L., Choi C. Y. K., Cai J. P., Tsoi H. W., Chu A. W. H., et al. (2022). Impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant-associated receptor binding domain (RBD) mutations on the susceptibility to serum antibodies elicited by coronavirus disease 2019 (COVID-19) infection or vaccination. Clin. Infect. Dis. 74, 1623–1630. 10.1093/cid/ciab656</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab656</ArticleId><ArticleId IdType="pubmed">34309648</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S. A., Arutyunova E., Lu J., Khan M. B., Rut W., Zmudzinski M., et al. (2023). SARS-CoV-2 Mpro protease variants of concern display altered viral substrate and cell host target galectin-8 processing but retain sensitivity toward antivirals. ACS Central Sci. 9, 696–708. 10.1021/acscentsci.3c00054</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.3c00054</ArticleId><ArticleId IdType="pmc">PMC10042146</ArticleId><ArticleId IdType="pubmed">37122453</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheohen C. F. d. A. R., Esteves M. E. A., da Fonseca T. S., Leal C. M., Assis F. d. L. F., Campos M. F., et al. (2023). In silico screening of phenylethanoid glycosides, a class of pharmacologically active compounds as natural inhibitors of SARS-CoV-2 proteases. Comput. Struct. Biotechnol. J. 21, 1461–1472. 10.1016/j.csbj.2023.02.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2023.02.020</ArticleId><ArticleId IdType="pmc">PMC9920770</ArticleId><ArticleId IdType="pubmed">36817956</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiou W. C., Hsu M. S., Chen Y. T., Yang J. M., Tsay Y. G., Huang H. C., et al. (2021). Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. J. Enzyme Inhib. Med. Chem. 36, 147–153. 10.1080/14756366.2020.1850710</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14756366.2020.1850710</ArticleId><ArticleId IdType="pmc">PMC7808739</ArticleId><ArticleId IdType="pubmed">33430659</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper B. S., Evans S., Jafari Y., Pham T. M., Mo Y., Lim C., et al. (2023). The burden and dynamics of hospital-acquired SARS-CoV-2 in England. Nature 623, 132–138. 10.1038/s41586-023-06634-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06634-z</ArticleId><ArticleId IdType="pmc">PMC10620085</ArticleId><ArticleId IdType="pubmed">37853126</ArticleId></ArticleIdList></Reference><Reference><Citation>Cucinotta D., Vanelli M. (2020). WHO declares COVID-19 a pandemic. Acta Biomed. 91, 157–160. 10.23750/abm.v91i1.9397</Citation><ArticleIdList><ArticleId IdType="doi">10.23750/abm.v91i1.9397</ArticleId><ArticleId IdType="pmc">PMC7569573</ArticleId><ArticleId IdType="pubmed">32191675</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai W., Zhang B., Jiang X. M., Su H., Li J., Zhao Y., et al. (2020). Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368, 1331–1335. 10.1126/science.abb4489</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb4489</ArticleId><ArticleId IdType="pmc">PMC7179937</ArticleId><ArticleId IdType="pubmed">32321856</ArticleId></ArticleIdList></Reference><Reference><Citation>Daina A., Michielin O., Zoete V. (2017). SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7, 42717. 10.1038/srep42717</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep42717</ArticleId><ArticleId IdType="pmc">PMC5335600</ArticleId><ArticleId IdType="pubmed">28256516</ArticleId></ArticleIdList></Reference><Reference><Citation>Essmann U., Perera L., Berkowitz M. L., Darden T., Lee H., Pedersen L. G. (1995). A smooth particle mesh Ewald method. J. Chem. Phys. 103, 8577–8593. 10.1063/1.470117</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/1.470117</ArticleId></ArticleIdList></Reference><Reference><Citation>Feller S. E., Zhang Y., Pastor R. W., Brooks B. R. (1995). Constant pressure molecular dynamics simulation: the Langevin piston method. J. Chem. Phys. 103, 4613–4621. 10.1063/1.470648</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/1.470648</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira J. C., Fadl S., Rabeh W. M. (2022). Key dimer interface residues impact the catalytic activity of 3CLpro, the main protease of SARS-CoV-2. J. Biol. Chem. 298, 102023. 10.1016/j.jbc.2022.102023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2022.102023</ArticleId><ArticleId IdType="pmc">PMC9091064</ArticleId><ArticleId IdType="pubmed">35568197</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira J. C., Fadl S., Villanueva A. J., Rabeh W. M. (2021). Catalytic dyad residues His41 and Cys145 impact the catalytic activity and overall conformational fold of the main SARS-CoV-2 protease 3-chymotrypsin-like protease. Front. Chem. 9, 692168. 10.3389/fchem.2021.692168</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2021.692168</ArticleId><ArticleId IdType="pmc">PMC8264439</ArticleId><ArticleId IdType="pubmed">34249864</ArticleId></ArticleIdList></Reference><Reference><Citation>Flynn J. M., Samant N., Schneider-Nachum G., Barkan D. T., Yilmaz N. K., Schiffer C. A., et al. (2022). Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms. eLife 11, e77433. 10.7554/eLife.77433</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.77433</ArticleId><ArticleId IdType="pmc">PMC9323007</ArticleId><ArticleId IdType="pubmed">35723575</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge R., Shen Z., Yin J., Chen W., Zhang Q., An Y., et al. (2022). Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection. SLAS Discov. 27, 79–85. 10.1016/j.slasd.2022.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.slasd.2022.01.001</ArticleId><ArticleId IdType="pmc">PMC8767972</ArticleId><ArticleId IdType="pubmed">35063690</ArticleId></ArticleIdList></Reference><Reference><Citation>Geethakumari A. M., Ahmed W. S., Rasool S., Fatima A., Nasir Uddin S. M., Aouida M., et al. (2022a). A genetically encoded BRET-based SARS-CoV-2 M(pro) protease activity sensor. Commun. Chem. 5, 117. 10.1038/s42004-022-00731-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42004-022-00731-2</ArticleId><ArticleId IdType="pmc">PMC9516532</ArticleId><ArticleId IdType="pubmed">36187754</ArticleId></ArticleIdList></Reference><Reference><Citation>Geethakumari A. M., Ahmed W. S., Rasool S., Fatima A., Uddin S. N., Aouida M., et al. (2022b). A Genetically encoded BRET-based SARS-CoV-2 Mpro protease activity sensor. bioRxiv 2022.2001.2031, 478460. 10.1101/2022.01.31.478460</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.31.478460</ArticleId><ArticleId IdType="pmc">PMC9516532</ArticleId><ArticleId IdType="pubmed">36187754</ArticleId></ArticleIdList></Reference><Reference><Citation>Golob J. L., Lugogo N., Lauring A. S., Lok A. S. (2021). SARS-CoV-2 vaccines: a triumph of science and collaboration. JCI insight 6, e149187. 10.1172/jci.insight.149187</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.149187</ArticleId><ArticleId IdType="pmc">PMC8262277</ArticleId><ArticleId IdType="pubmed">33822773</ArticleId></ArticleIdList></Reference><Reference><Citation>Grum-Tokars V., Ratia K., Begaye A., Baker S. C., Mesecar A. D. (2008). Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery. Virus Res. 133, 63–73. 10.1016/j.virusres.2007.02.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2007.02.015</ArticleId><ArticleId IdType="pmc">PMC4036818</ArticleId><ArticleId IdType="pubmed">17397958</ArticleId></ArticleIdList></Reference><Reference><Citation>Günther S., Reinke P. Y. A., Fernández-García Y., Lieske J., Lane T. J., Ginn H. M., et al. (2021). X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science 372, 642–646. 10.1126/science.abf7945</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf7945</ArticleId><ArticleId IdType="pmc">PMC8224385</ArticleId><ArticleId IdType="pubmed">33811162</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall V., Foulkes S., Insalata F., Kirwan P., Saei A., Atti A., et al. (2022). Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N. Engl. J. Med. 386, 1207–1220. 10.1056/NEJMoa2118691</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118691</ArticleId><ArticleId IdType="pmc">PMC8908850</ArticleId><ArticleId IdType="pubmed">35172051</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison A. G., Lin T., Wang P. (2020). Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 41, 1100–1115. 10.1016/j.it.2020.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2020.10.004</ArticleId><ArticleId IdType="pmc">PMC7556779</ArticleId><ArticleId IdType="pubmed">33132005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Q., Xiong Y., Zhu G. H., Zhang Y. N., Zhang Y. W., Huang P., et al. (2022). The SARS-CoV-2 main protease (Mpro): structure, function, and emerging therapies for COVID-19. MedComm 3, e151. 10.1002/mco2.151</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.151</ArticleId><ArticleId IdType="pmc">PMC9283855</ArticleId><ArticleId IdType="pubmed">35845352</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Rauscher S., Nawrocki G., Ran T., Feig M., de Groot B. L., et al. (2017). CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat. methods 14, 71–73. 10.1038/nmeth.4067</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4067</ArticleId><ArticleId IdType="pmc">PMC5199616</ArticleId><ArticleId IdType="pubmed">27819658</ArticleId></ArticleIdList></Reference><Reference><Citation>Huespe I. A., Ferraris A., Lalueza A., Valdez P. R., Peroni M. L., Cayetti L. A., et al. (2023). COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: differences between vaccine subtypes. A multicontinental cohort study. J. Med. Virol. 95, e28786. 10.1002/jmv.28786</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28786</ArticleId><ArticleId IdType="pubmed">37212340</ArticleId></ArticleIdList></Reference><Reference><Citation>Huff S., Kummetha I. R., Tiwari S. K., Huante M. B., Clark A. E., Wang S., et al. (2022). Discovery and mechanism of SARS-CoV-2 main protease inhibitors. J. Med. Chem. 65, 2866–2879. 10.1021/acs.jmedchem.1c00566</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c00566</ArticleId><ArticleId IdType="pmc">PMC8491550</ArticleId><ArticleId IdType="pubmed">34570513</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey W., Dalke A., Schulten K. (1996). VMD: visual molecular dynamics. J. Mol. Graph. 14, 33–38. 10.1016/0263-7855(96)00018-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0263-7855(96)00018-5</ArticleId><ArticleId IdType="pubmed">8744570</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin J. J., Shoichet B. K. (2005). ZINC--a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model 45, 177–182. 10.1021/ci049714+</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ci049714+</ArticleId><ArticleId IdType="pmc">PMC1360656</ArticleId><ArticleId IdType="pubmed">15667143</ArticleId></ArticleIdList></Reference><Reference><Citation>
Jackson J. K.
Overview (2022). in Global economic effects of COVID-19. Available at: https://crsreports.congress.gov/product/pdf/R/R46270/84.
</Citation></Reference><Reference><Citation>Jan Z., Ahmed W. S., Biswas K. H., Jithesh P. V. (2023b). Identification of a potential DNA methyltransferase (DNMT) inhibitor. J. Biomol. Struct. and Dyn. 1-15. 10.1080/07391102.2023.2233637</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2023.2233637</ArticleId><ArticleId IdType="pubmed">37424222</ArticleId></ArticleIdList></Reference><Reference><Citation>Jan Z., Geethakumari A. M., Biswas K. H., Jithesh P. V. (2023a). Protegrin-2, a potential inhibitor for targeting SARS-CoV-2 main protease Mpro. Comput. Struct. Biotechnol. J. 21, 3665–3671. 10.1016/j.csbj.2023.07.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2023.07.020</ArticleId><ArticleId IdType="pmc">PMC10412832</ArticleId><ArticleId IdType="pubmed">37576748</ArticleId></ArticleIdList></Reference><Reference><Citation>Jangra S., Ye C., Rathnasinghe R., Stadlbauer D., Krammer F., Simon V., et al. (2021). SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe 2, e283–e284. 10.1016/s2666-5247(21)00068-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2666-5247(21)00068-9</ArticleId><ArticleId IdType="pmc">PMC8026167</ArticleId><ArticleId IdType="pubmed">33846703</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiménez-Avalos G., Vargas-Ruiz A. P., Delgado-Pease N. E., Olivos-Ramirez G. E., Sheen P., Fernández-Díaz M., et al. (2021). Comprehensive virtual screening of 4.8 k flavonoids reveals novel insights into allosteric inhibition of SARS-CoV-2 M(PRO). Sci. Rep. 11, 15452. 10.1038/s41598-021-94951-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-94951-6</ArticleId><ArticleId IdType="pmc">PMC8322093</ArticleId><ArticleId IdType="pubmed">34326429</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., et al. (2020). Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 582, 289–293. 10.1038/s41586-020-2223-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2223-y</ArticleId><ArticleId IdType="pubmed">32272481</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo S., Kim T., Iyer V. G., Im W.CHARMM.-G. U. I. (2008). CHARMM-GUI: a web-based graphical user interface for CHARMM. J. Comput. Chem. 29, 1859–1865. 10.1002/jcc.20945</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20945</ArticleId><ArticleId IdType="pubmed">18351591</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen W. L., Chandrasekhar J., Madura J. D., Impey R. W., Klein M. L. (1983). Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79, 926–935. 10.1063/1.445869</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/1.445869</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaptan S., Girych M., Enkavi G., Kulig W., Sharma V., Vuorio J., et al. (2022). Maturation of the SARS-CoV-2 virus is regulated by dimerization of its main protease. Comput. Struct. Biotechnol. J. 20, 3336–3346. 10.1016/j.csbj.2022.06.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2022.06.023</ArticleId><ArticleId IdType="pmc">PMC9195460</ArticleId><ArticleId IdType="pubmed">35720615</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalaf K., Papp N., Chou J. T. T., Hana D., Mackiewicz A., Kaczmarek M. (2020). SARS-CoV-2: pathogenesis, and advancements in diagnostics and treatment. Front. Immunol. 11, 570927. 10.3389/fimmu.2020.570927</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.570927</ArticleId><ArticleId IdType="pmc">PMC7573101</ArticleId><ArticleId IdType="pubmed">33123144</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollman P., Massova I., Reyes C., Kuhn B., Huo S., Chong L., et al. (2000). Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. 33, 889–897. 10.1021/ar000033j</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ar000033j</ArticleId><ArticleId IdType="pubmed">11123888</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers M. M., Haagmans B. L. (2022). SARS-CoV-2 pathogenesis. Nat. Rev. Microbiol. 20, 270–284. 10.1038/s41579-022-00713-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00713-0</ArticleId><ArticleId IdType="pubmed">35354968</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Kenward C., Worrall L. J., Vuckovic M., Gentile F., Ton A. T., et al. (2022). X-ray crystallographic characterization of the SARS-CoV-2 main protease polyprotein cleavage sites essential for viral processing and maturation. Nat. Commun. 13, 5196. 10.1038/s41467-022-32854-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32854-4</ArticleId><ArticleId IdType="pmc">PMC9440467</ArticleId><ArticleId IdType="pubmed">36057636</ArticleId></ArticleIdList></Reference><Reference><Citation>Legare S., Heide F., Bailey-Elkin B. A., Stetefeld J. (2022). Improved SARS-CoV-2 main protease high-throughput screening assay using a 5-carboxyfluorescein substrate. J. Biol. Chem. 298, 101739. 10.1016/j.jbc.2022.101739</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2022.101739</ArticleId><ArticleId IdType="pmc">PMC8849842</ArticleId><ArticleId IdType="pubmed">35182525</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Leung K. S., Wong M. H. (2012). in 2012 IEEE symposium on computational intelligence in bioinformatics and computational biology (CIBCB), 77–84.</Citation></Reference><Reference><Citation>Liu H., Hou T. (2016). CaFE: a tool for binding affinity prediction using end-point free energy methods. Bioinforma. Oxf. Engl. 32, 2216–2218. 10.1093/bioinformatics/btw215</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btw215</ArticleId><ArticleId IdType="pubmed">27153651</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J., Chen S. A., Khan M. B., Brassard R., Arutyunova E., Lamer T., et al. (2022). Crystallization of feline coronavirus Mpro with GC376 reveals mechanism of inhibition. Front. Chem. 10, 852210. 10.3389/fchem.2022.852210</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2022.852210</ArticleId><ArticleId IdType="pmc">PMC8907848</ArticleId><ArticleId IdType="pubmed">35281564</ArticleId></ArticleIdList></Reference><Reference><Citation>Luan X.-d., Chen B. X., Shang W. J., Yin W. C., Jin Y., Zhang L. K., et al. (2023). Structure basis for inhibition of SARS-CoV-2 by the feline drug GC376. Acta Pharmacol. Sin. 44, 255–257. 10.1038/s41401-022-00929-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-022-00929-z</ArticleId><ArticleId IdType="pmc">PMC9243920</ArticleId><ArticleId IdType="pubmed">35773339</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig S., Zarbock A. (2020). Coronaviruses and SARS-CoV-2: a brief overview. Anesth. analgesia 131, 93–96. 10.1213/ANE.0000000000004845</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0000000000004845</ArticleId><ArticleId IdType="pmc">PMC7173023</ArticleId><ArticleId IdType="pubmed">32243297</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullagh M., Zeczycki T. N., Kariyawasam C. S., Durie C. L., Halkidis K., Fitzkee N. C., et al. (2024). What is allosteric regulation? Exploring the exceptions that prove the rule. J. Biol. Chem. 300, 105672. 10.1016/j.jbc.2024.105672</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2024.105672</ArticleId><ArticleId IdType="pmc">PMC10897898</ArticleId><ArticleId IdType="pubmed">38272229</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean G., Kamil J., Lee B., Moore P., Schulz T. F., Muik A., et al. (2022). The impact of evolving SARS-CoV-2 mutations and variants on COVID-19 vaccines. mBio 13, e0297921. 10.1128/mbio.02979-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.02979-21</ArticleId><ArticleId IdType="pmc">PMC9040821</ArticleId><ArticleId IdType="pubmed">35352979</ArticleId></ArticleIdList></Reference><Reference><Citation>Mihalic F., Benz C., Kassa E., Lindqvist R., Simonetti L., Inturi R., et al. (2023). Identification of motif-based interactions between SARS-CoV-2 protein domains and human peptide ligands pinpoint antiviral targets. Nat. Commun. 14, 5636. 10.1038/s41467-023-41312-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-41312-8</ArticleId><ArticleId IdType="pmc">PMC10499821</ArticleId><ArticleId IdType="pubmed">37704626</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller I. F., Becker A. D., Grenfell B. T., Metcalf C. J. E. (2020). Disease and healthcare burden of COVID-19 in the United States. Nat Med. 10.1038/s41591-020-0952-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0952-y</ArticleId><ArticleId IdType="pubmed">32546823</ArticleId></ArticleIdList></Reference><Reference><Citation>Mistry P., Barmania F., Mellet J., Peta K., Strydom A., Viljoen I. M., et al. (2022). SARS-CoV-2 variants, vaccines, and host immunity. Front. Immunol. 12, 809244. 10.3389/fimmu.2021.809244</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.809244</ArticleId><ArticleId IdType="pmc">PMC8761766</ArticleId><ArticleId IdType="pubmed">35046961</ArticleId></ArticleIdList></Reference><Reference><Citation>Moovarkumudalvan B., Geethakumari A. M., Ramadoss R., Biswas K. H., Mifsud B. (2022). Structure-based virtual screening and functional validation of potential hit molecules targeting the SARS-CoV-2 main protease. Biomolecules 12, 1754. 10.3390/biom12121754</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom12121754</ArticleId><ArticleId IdType="pmc">PMC9775371</ArticleId><ArticleId IdType="pubmed">36551182</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan A., Narwal M., Majowicz S. A., Varricchio C., Toner S. A., Ballatore C., et al. (2022). Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay. Commun. Biol. 5, 169. 10.1038/s42003-022-03090-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-022-03090-9</ArticleId><ArticleId IdType="pmc">PMC8881501</ArticleId><ArticleId IdType="pubmed">35217718</ArticleId></ArticleIdList></Reference><Reference><Citation>Noske G. D., de Souza Silva E., de Godoy M. O., Dolci I., Fernandes R. S., Guido R. V. C., et al. (2023). Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease. J. Biol. Chem. 299, 103004. 10.1016/j.jbc.2023.103004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2023.103004</ArticleId><ArticleId IdType="pmc">PMC9916189</ArticleId><ArticleId IdType="pubmed">36775130</ArticleId></ArticleIdList></Reference><Reference><Citation>Paciaroni A., Libera V., Ripanti F., Orecchini A., Petrillo C., Francisci D., et al. (2023). Stabilization of the dimeric state of SARS-CoV-2 main protease by GC376 and nirmatrelvir. Int. J. Mol. Sci. 24, 6062. 10.3390/ijms24076062</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24076062</ArticleId><ArticleId IdType="pmc">PMC10093836</ArticleId><ArticleId IdType="pubmed">37047038</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang X., Xu W., Liu Y., Li H., Chen L. (2023). The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022. Eur. J. Med. Chem. 257, 115491. 10.1016/j.ejmech.2023.115491</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2023.115491</ArticleId><ArticleId IdType="pmc">PMC10201905</ArticleId><ArticleId IdType="pubmed">37244162</ArticleId></ArticleIdList></Reference><Reference><Citation>Parmar M., Thumar R., Patel B., Athar M., Jha P. C., Patel D. (2022). Structural differences in 3C-like protease (Mpro) from SARS-CoV and SARS-CoV-2: molecular insights revealed by Molecular Dynamics Simulations. Struct. Chem., 1–18. 10.1007/s11224-022-02089-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11224-022-02089-6</ArticleId><ArticleId IdType="pmc">PMC9686461</ArticleId><ArticleId IdType="pubmed">36467259</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavlova A., Lynch D. L., Daidone I., Zanetti-Polzi L., Smith M. D., Chipot C., et al. (2021). Inhibitor binding influences the protonation states of histidines in SARS-CoV-2 main protease. Chem. Sci. 12, 1513–1527. 10.1039/d0sc04942e</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/d0sc04942e</ArticleId><ArticleId IdType="pmc">PMC8899719</ArticleId><ArticleId IdType="pubmed">35356437</ArticleId></ArticleIdList></Reference><Reference><Citation>Philip A. M., Ahmed W. S., Biswas K. H. (2023). Reversal of the unique Q493R mutation increases the affinity of Omicron S1-RBD for ACE2. Comput. Struct. Biotechnol. J. 21, 1966–1977. 10.1016/j.csbj.2023.02.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2023.02.019</ArticleId><ArticleId IdType="pmc">PMC10006685</ArticleId><ArticleId IdType="pubmed">36936816</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips J. C., Braun R., Wang W., Gumbart J., Tajkhorshid E., Villa E., et al. (2005). Scalable molecular dynamics with NAMD. J. Comput. Chem. 26, 1781–1802. 10.1002/jcc.20289</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20289</ArticleId><ArticleId IdType="pmc">PMC2486339</ArticleId><ArticleId IdType="pubmed">16222654</ArticleId></ArticleIdList></Reference><Reference><Citation>Puhl A. C., Zorn K. M., Lane T. R., Russo D. P., Klein J. J., et al. (2019). Exploiting machine learning for end-to-end drug discovery and development. Nat. Mater. 18, 435–441. 10.1038/s41563-019-0338-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41563-019-0338-z</ArticleId><ArticleId IdType="pmc">PMC6594828</ArticleId><ArticleId IdType="pubmed">31000803</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindranath P. A., Forli S., Goodsell D. S., Olson A. J., Sanner M. F. (2015). AutoDockFR: advances in protein-ligand docking with explicitly specified binding site flexibility. PLoS Comput. Biol. 11, e1004586. 10.1371/journal.pcbi.1004586</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1004586</ArticleId><ArticleId IdType="pmc">PMC4667975</ArticleId><ArticleId IdType="pubmed">26629955</ArticleId></ArticleIdList></Reference><Reference><Citation>Robson B. (2020). Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus. Comput. Biol. Med. 119, 103670. 10.1016/j.compbiomed.2020.103670</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiomed.2020.103670</ArticleId><ArticleId IdType="pmc">PMC7094376</ArticleId><ArticleId IdType="pubmed">32209231</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossetti G. G., Ossorio M. A., Rempel S., Kratzel A., Dionellis V. S., Barriot S., et al. (2022). Non-covalent SARS-CoV-2 M(pro) inhibitors developed from in silico screen hits. Sci. Rep. 12, 2505. 10.1038/s41598-022-06306-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-06306-4</ArticleId><ArticleId IdType="pmc">PMC8847420</ArticleId><ArticleId IdType="pubmed">35169179</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbah D. A., Hajjo R., Bardaweel S. K., Zhong H. A. (2021). An updated review on SARS-CoV-2 main proteinase (M(pro)): protein structure and small-molecule inhibitors. Curr. Top. Med. Chem. 21, 442–460. 10.2174/1568026620666201207095117</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026620666201207095117</ArticleId><ArticleId IdType="pubmed">33292134</ArticleId></ArticleIdList></Reference><Reference><Citation>Salje H., Tran Kiem C., Lefrancq N., Courtejoie N., Bosetti P., Paireau J., et al. (2020). Estimating the burden of SARS-CoV-2 in France. Science 369, 208–211. 10.1126/science.abc3517</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc3517</ArticleId><ArticleId IdType="pmc">PMC7223792</ArticleId><ArticleId IdType="pubmed">32404476</ArticleId></ArticleIdList></Reference><Reference><Citation>Samrat S. K., Xu J., Xie X., Gianti E., Chen H., Zou J., et al. (2022). Allosteric inhibitors of the main protease of SARS-CoV-2. Antivir. Res. 205, 105381. 10.1016/j.antiviral.2022.105381</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2022.105381</ArticleId><ArticleId IdType="pmc">PMC9272661</ArticleId><ArticleId IdType="pubmed">35835291</ArticleId></ArticleIdList></Reference><Reference><Citation>Schütz D., Ruiz-Blanco Y. B., Münch J., Kirchhoff F., Sanchez-Garcia E., Müller J. A. (2020). Peptide and peptide-based inhibitors of SARS-CoV-2 entry. Adv. Drug Deliv. Rev. 167, 47–65. 10.1016/j.addr.2020.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2020.11.007</ArticleId><ArticleId IdType="pmc">PMC7665879</ArticleId><ArticleId IdType="pubmed">33189768</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaqra A. M., Zvornicanin S. N., Huang Q. Y. J., Lockbaum G. J., Knapp M., Tandeske L., et al. (2022). Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance. Nat. Commun. 13, 3556. 10.1038/s41467-022-31210-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31210-w</ArticleId><ArticleId IdType="pmc">PMC9211792</ArticleId><ArticleId IdType="pubmed">35729165</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharun K., Tiwari R., Dhama K. (2021). Protease inhibitor GC376 for COVID-19: lessons learned from feline infectious peritonitis. Ann. Med. Surg. (Lond) 61, 122–125. 10.1016/j.amsu.2020.12.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2020.12.030</ArticleId><ArticleId IdType="pmc">PMC7797473</ArticleId><ArticleId IdType="pubmed">33456770</ArticleId></ArticleIdList></Reference><Reference><Citation>Shree P., Mishra P., Selvaraj C., Singh S. K., Chaube R., Garg N., et al. (2022). Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants - withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi) - a molecular docking study. J. Biomol. Struct. Dyn. 40, 1–14. 10.1080/07391102.2020.1810778</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1810778</ArticleId><ArticleId IdType="pmc">PMC7484581</ArticleId><ArticleId IdType="pubmed">32851919</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinbach P. J., Brooks B. R. (1994). New spherical‐cutoff methods for long‐range forces in macromolecular simulation. J. Comput. Chem. 15, 667–683. 10.1002/jcc.540150702</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.540150702</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterling T., Irwin J. J. (2015). ZINC 15--ligand discovery for everyone. J. Chem. Inf. Model 55, 2324–2337. 10.1021/acs.jcim.5b00559</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.5b00559</ArticleId><ArticleId IdType="pmc">PMC4658288</ArticleId><ArticleId IdType="pubmed">26479676</ArticleId></ArticleIdList></Reference><Reference><Citation>Strömich L., Wu N., Barahona M., Yaliraki S. N. (2022). Allosteric hotspots in the main protease of SARS-CoV-2. J. Mol. Biol. 434, 167748. 10.1016/j.jmb.2022.167748</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2022.167748</ArticleId><ArticleId IdType="pmc">PMC9288249</ArticleId><ArticleId IdType="pubmed">35843284</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z., Wang L., Li X., Fan C., Xu J., Shi Z., et al. (2022). An extended conformation of SARS-CoV-2 main protease reveals allosteric targets. Proc. Natl. Acad. Sci. 119, e2120913119. 10.1073/pnas.2120913119</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2120913119</ArticleId><ArticleId IdType="pmc">PMC9169858</ArticleId><ArticleId IdType="pubmed">35324337</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao K., Tzou P. L., Nouhin J., Gupta R. K., de Oliveira T., Kosakovsky Pond S. L., et al. (2021a). The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet. 22, 757–773. 10.1038/s41576-021-00408-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41576-021-00408-x</ArticleId><ArticleId IdType="pmc">PMC8447121</ArticleId><ArticleId IdType="pubmed">34535792</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao K., Tzou P. L., Nouhin J., Gupta R. K., de Oliveira T., Kosakovsky Pond S. L., et al. (2021b). The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet. 22, 757–773. 10.1038/s41576-021-00408-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41576-021-00408-x</ArticleId><ArticleId IdType="pmc">PMC8447121</ArticleId><ArticleId IdType="pubmed">34535792</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao X., Zhang L., Du L., Liao R., Cai H., Lu K., et al. (2021c). Allosteric inhibition of SARS-CoV-2 3CL protease by colloidal bismuth subcitrate. Chem. Sci. 12, 14098–14102. 10.1039/d1sc03526f</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/d1sc03526f</ArticleId><ArticleId IdType="pmc">PMC8565384</ArticleId><ArticleId IdType="pubmed">34760193</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee W. V., Berezovsky I. N. (2024). Allosteric drugs: new principles and design approaches. Curr. Opin. Struct. Biol. 84, 102758. 10.1016/j.sbi.2023.102758</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2023.102758</ArticleId><ArticleId IdType="pubmed">38171188</ArticleId></ArticleIdList></Reference><Reference><Citation>Trott O., Olson A. J. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455–461. 10.1002/jcc.21334</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.21334</ArticleId><ArticleId IdType="pmc">PMC3041641</ArticleId><ArticleId IdType="pubmed">19499576</ArticleId></ArticleIdList></Reference><Reference><Citation>Trougakos I. P., Stamatelopoulos K., Terpos E., Tsitsilonis O. E., Aivalioti E., Paraskevis D., et al. (2021). Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J. Biomed. Sci. 28 (9), 9. 10.1186/s12929-020-00703-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-020-00703-5</ArticleId><ArticleId IdType="pmc">PMC7801873</ArticleId><ArticleId IdType="pubmed">33435929</ArticleId></ArticleIdList></Reference><Reference><Citation>Tumskiy R. S., Tumskaia A. V., Klochkova I. N., Richardson R. J. (2023). SARS-CoV-2 proteases Mpro and PLpro: design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations. Comput. Biol. Med. 153, 106449. 10.1016/j.compbiomed.2022.106449</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiomed.2022.106449</ArticleId><ArticleId IdType="pmc">PMC9788855</ArticleId><ArticleId IdType="pubmed">36586228</ArticleId></ArticleIdList></Reference><Reference><Citation>Uddin S. M. N., Rasool S., Geethakumari A. M., Ahmed W. S., Biswas K. H. (2024). Engineering β-catenin-derived peptides for α-catenin binding. Emergent Mater. 10.1007/s42247-024-00663-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42247-024-00663-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Uwamino Y., Yokoyama T., Shimura T., Nishimura T., Sato Y., Wakui M., et al. (2022). The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals. Vaccine 40, 1928–1931. 10.1016/j.vaccine.2022.02.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.02.047</ArticleId><ArticleId IdType="pmc">PMC8841208</ArticleId><ArticleId IdType="pubmed">35183387</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma S., Pandey A. K. (2021). Factual insights of the allosteric inhibition mechanism of SARS-CoV-2 main protease by quercetin: an in silico analysis. 3 Biotech. 11, 67. 10.1007/s13205-020-02630-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13205-020-02630-6</ArticleId><ArticleId IdType="pmc">PMC7802979</ArticleId><ArticleId IdType="pubmed">33457176</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicenti I., Zazzi M., Saladini F. (2021). SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert Opin. Ther. Pat. 31, 325–337. 10.1080/13543776.2021.1880568</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543776.2021.1880568</ArticleId><ArticleId IdType="pmc">PMC7938656</ArticleId><ArticleId IdType="pubmed">33475441</ArticleId></ArticleIdList></Reference><Reference><Citation>V’kovski P., Kratzel A., Steiner S., Stalder H., Thiel V. (2021). Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 19, 155–170. 10.1038/s41579-020-00468-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00468-6</ArticleId><ArticleId IdType="pmc">PMC7592455</ArticleId><ArticleId IdType="pubmed">33116300</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkamer A., Griewel A., Grombacher T., Rarey M. (2010). Analyzing the topology of active sites: on the prediction of pockets and subpockets. J. Chem. Inf. Model. 50, 2041–2052. 10.1021/ci100241y</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ci100241y</ArticleId><ArticleId IdType="pubmed">20945875</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkamer A., Kuhn D., Rippmann F., Rarey M. (2012). DoGSiteScorer: a web server for automatic binding site prediction, analysis and druggability assessment. Bioinformatics 28, 2074–2075. 10.1093/bioinformatics/bts310</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts310</ArticleId><ArticleId IdType="pubmed">22628523</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenthur C. J., Gentry P. R., Mathews T. P., Lindsley C. W. (2014). Drugs for allosteric sites on receptors. Annu. Rev. Pharmacol. Toxicol. 54, 165–184. 10.1146/annurev-pharmtox-010611-134525</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-010611-134525</ArticleId><ArticleId IdType="pmc">PMC4063350</ArticleId><ArticleId IdType="pubmed">24111540</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wl D. (2002). The PyMOL molecular graphics system. Available at: http://www.pymol.org.
</Citation></Reference><Reference><Citation>Wu D., Wu T., Liu Q., Yang Z. Z. (2020). The SARS-CoV-2 outbreak: What we know. Int J Infect Dis. 94:44–48. 10.1016/j.ijid.2020.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.03.004</ArticleId><ArticleId IdType="pmc">PMC7102543</ArticleId><ArticleId IdType="pubmed">32171952</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu N., Barahona M., Yaliraki S. N. (2024). Allosteric communication and signal transduction in proteins. Curr. Opin. Struct. Biol. 84, 102737. 10.1016/j.sbi.2023.102737</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2023.102737</ArticleId><ArticleId IdType="pubmed">38171189</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue X., Yu H., Yang H., Xue F., Wu Z., Shen W., et al. (2008). Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J. Virol. 82, 2515–2527. 10.1128/jvi.02114-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.02114-07</ArticleId><ArticleId IdType="pmc">PMC2258912</ArticleId><ArticleId IdType="pubmed">18094151</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S., Chan H. S., Hu Z. (2017). Using PyMOL as a platform for computational drug design. Wiley Interdiscip. Rev. Comput. Mol. Sci. 7, e1298. 10.1002/wcms.1298</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wcms.1298</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuce M., Cicek E., Inan T., Dag A. B., Kurkcuoglu O., Sungur F. A. (2021). Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease. Proteins 89, 1425–1441. 10.1002/prot.26164</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.26164</ArticleId><ArticleId IdType="pmc">PMC8441840</ArticleId><ArticleId IdType="pubmed">34169568</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., et al. (2020). Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 368, 409–412. 10.1126/science.abb3405</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb3405</ArticleId><ArticleId IdType="pmc">PMC7164518</ArticleId><ArticleId IdType="pubmed">32198291</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>